INTRODUCTION {#s1}
============

The neural crest is a transient embryonic structure that originates from the neural fold during vertebrate development. Neural crest cells migrate to various embryonic regions, where they differentiate into a wide range of cells, including peripheral neurons and their supportive cells, pigment cells, skeletal derivatives, and smooth muscle cells ([@BIO021758C24]; [@BIO021758C43]). Although some of the neural crest cells undergo developmental restrictions, some instead maintain their multipotency even after having entered target tissues ([@BIO021758C50]) and form neural crest-derived stem cells (NCSCs) ([@BIO021758C70]; [@BIO021758C1]; [@BIO021758C19]; [@BIO021758C71]). It has been reported that NCSCs exist in late embryonic and adult tissues such as dorsal root ganglion (DRG) ([@BIO021758C22]; [@BIO021758C66]; [@BIO021758C45]), sciatic nerve ([@BIO021758C49]; [@BIO021758C35]), gut ([@BIO021758C39]; [@BIO021758C7]), bone marrow ([@BIO021758C54]), cornea ([@BIO021758C92]), heart ([@BIO021758C83]), and skin ([@BIO021758C72]; [@BIO021758C89]).

A recent investigation demonstrated that neural crest cells generate not only ectodermal and mesodermal phenotypes, but also endodermal phenotypes in *Xenopus* ([@BIO021758C8]). Furthermore, it has been shown that mammalian neural crest cells express pluripotency-related transcription factors ([@BIO021758C80]; [@BIO021758C23]), including octamer-binding transcription factor 4 (Oct4), SRY (sex determining region Y)-box containing gene (Sox) 2, and Nanog, and play important roles in the maintenance of pluripotency of embryonic stem (ES) cells ([@BIO021758C56]). Thus, NCSCs that possess multipotency may have the characteristics of pluripotent stem cells (PSCs). In addition, several types of tissue-specific stem cells are capable of differentiating into ectoderm-, mesoderm-, and endoderm-derived cells. They have been shown to be present in bone marrow ([@BIO021758C18]), oral mucosa ([@BIO021758C46]), dental pulp ([@BIO021758C2]), adipose tissue ([@BIO021758C36]), and skeletal muscle ([@BIO021758C86]).

Seventy percent of adult mouse DRG-derived cell spheres contain NCSCs, while only 3 to 7% of cell spheres that originate from other neural crest-derived tissues contain NCSCs ([@BIO021758C54]). In the present study, therefore, we investigated mouse embryonic DRGs to determine whether or not the DRGs contain PSCs, what conditions are essential for the maintenance of NCSCs and PSCs in the DRGs, and what correlation exists between PSCs and NCSCs in the DRGs.

RESULTS {#s2}
=======

Expression of pluripotency-related transcription factors and stage-specific embryonic antigen 1 (SSEA1) and activity of alkaline phosphatase in mouse embryonic DRGs {#s2a}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

We examined the expression of pluripotency-related transcription factors and SSEA1 and the activity of alkaline phosphatase in embryonic day (E)12 mouse DRGs. The DRG cells expressed Oct4 ([Fig. 1](#BIO021758F1){ref-type="fig"}B,E,G,J,L,O), Sox2 ([Fig. 1](#BIO021758F1){ref-type="fig"}C,E), Nanog ([Fig. 1](#BIO021758F1){ref-type="fig"}H,J) and/or SSEA1 ([Fig. 1](#BIO021758F1){ref-type="fig"}M,O). Furthermore, the DRGs contained cells expressing both Oct4 and Sox2 (white arrowheads in [Fig. 1](#BIO021758F1){ref-type="fig"}B′-E′), both Oct4 and Nanog (white arrowheads in [Fig. 1](#BIO021758F1){ref-type="fig"}G′-J′), or both Oct4 and SSEA1 (white arrowheads in [Fig. 1](#BIO021758F1){ref-type="fig"}L′-O′). Additionally, some of the DRG cells showed alkaline phosphatase activity ([Fig. 1](#BIO021758F1){ref-type="fig"}P,P′). Fig. 1.**Expression patterns of Oct4, Sox2, Nanog, and SSEA1 in mouse embryonic DRGs.** (A-O) Transverse sections of E12 mouse DRGs. The top, bottom, left, and right of each photograph correspond to the dorsal, ventral, proximal, and distal side of the embryo, respectively. (A) Bright-field image. (B) Expression pattern of Oct4 in the same field as A. (C) Expression pattern of Sox2 in the same field as A. (D) DAPI nuclear staining of the same field as A. (E) Merged image of B-D. (F) Bright-field image. (G) Expression pattern of Oct4 in the same field as F. (H) Expression pattern of Nanog in the same field as F. (I) DAPI nuclear staining of the same field as F. (J) Merged image of G-I. (K) Bright-field image. (L) Expression pattern of Oct4 in the same field as K. (M) Expression pattern of SSEA1 in the same field as K. (N) DAPI nuclear staining of the same field as K. (O) Merged image of L-N. (P) Alkaline phosphatase activity (purple) in mouse embryonic DRGs. Nuclei were stained by methyl green (blue). A′-E′,F′-J′,K′-O′, and P′ show enlarged images of boxed regions in A-E,F-J,K-O, and P, respectively. White arrowheads indicate cells expressing both Oct4 and Sox2 (B′-E′), both Oct4 and Nanog (G′-J′), and both Oct4 and SSEA1 (L′-O′). Scale bars: 20 µm.

Developmental capacities of mouse embryonic DRG cells {#s2b}
-----------------------------------------------------

We examined the developmental potentials of mouse embryonic DRG cells in culture. Since it has been reported that bone morphogenetic protein 4 (BMP4), fibroblast growth factor 2 (FGF2), and transforming growth factor-β (TGFβ) are factors that promote differentiation into neurons ([@BIO021758C64]), glia ([@BIO021758C64]), chondrocytes ([@BIO021758C31]), and smooth muscle cells ([@BIO021758C34]), respectively; we tested the effects of these factors when added to the culture medium ([Fig. 2](#BIO021758F2){ref-type="fig"}A). The DRG cells in explant cultures differentiated into neurons ([Fig. 2](#BIO021758F2){ref-type="fig"}B-E) in BMP4-treated cultures, into glia ([Fig. 2](#BIO021758F2){ref-type="fig"}F-I) in FGF2-treated cultures, into smooth muscle cells ([Fig. 2](#BIO021758F2){ref-type="fig"}J-M) in TGFβ-treated cultures, and into chondrocytes ([Fig. 2](#BIO021758F2){ref-type="fig"}N-Q) in FGF2-treated cultures. In contrast, activin A promotes differentiation into endoderm that expresses Sox17 and forkhead box protein A2 (Foxa2), markers of endodermal cells in the mouse ([@BIO021758C6]; [@BIO021758C67]; [@BIO021758C94]), in mouse ES cells ([@BIO021758C90]; [@BIO021758C69]). Therefore, we examined whether the DRG cells could differentiate into endoderm in the presence of activin A. Activin A-treated DRG cells indeed differentiated into endodermal cells expressing Sox17 ([Fig. 2](#BIO021758F2){ref-type="fig"}R-U) or Foxa2 ([Fig. 2](#BIO021758F2){ref-type="fig"}V-Y). Fig. 2.**Developmental capacities of mouse embryonic DRG cells in explant cultures.** (A) E12 mouse DRG explants were exposed to various differentiation-promoting factors for 4 or 6 days. Immunostaining was performed by using anti-NF68, anti-GFAP, anti-SMA, anti-Collagen type II, anti-Sox17, or anti-Foxa2 on culture day 4 or 6. (B) Bright-field image. (C) Anti-NF68-positive cells in the same field as B. (D) DAPI nuclear staining of the same field as B. (E) Merged image of C and D. (F) Bright-field image. (G) Anti-GFAP-positive cells in the same field as F. (H) DAPI nuclear staining of the same field as F. (I) Merged image of G and H. (J) Bright-field image. (K) Anti-SMA-positive cells in the same field as J. (L) DAPI nuclear staining of the same field as J. (M) Merged image of K and L. (N) Bright-field image. (O) Anti-Collagen type II-positive cells in the same field as N. (P) DAPI nuclear staining of the same field as N. (Q) Merged image of O and P. (R) Bright-field image. (S) Anti-Sox17-positive cells in the same field as R. (T) DAPI nuclear staining of the same field as R. (U) Merged image of S and T. (V) Bright-field image. (W) Anti-Foxa2-positive cells in the same field as V. (X) DAPI nuclear staining of the same field as V. (Y) Merged image of W and X. Scale bars: 50 µm.

Furthermore, we performed clonal culture analysis to investigate the developmental capacities of single DRG cells. We previously reported that the DRG cells could differentiated into smooth muscle cells even in the absence of TGFβ ([@BIO021758C21]). In clonal cultures, therefore, we did not use TGFβ to induce the differentiation into smooth muscle cells. We detected clones containing both smooth muscle cells ([Fig. 3](#BIO021758F3){ref-type="fig"}A,D) and neurons ([Fig. 3](#BIO021758F3){ref-type="fig"}B,D) in BMP4-treated cultures. We also found clones containing both smooth muscle cells ([Fig. 3](#BIO021758F3){ref-type="fig"}E,H) and endodermal cells expressing Foxa2 ([Fig. 3](#BIO021758F3){ref-type="fig"}F,H) in activin A-treated cultures. Clones containing cells which express both glial fibrillary acidic protein (GFAP) and Foxa2 ([Fig. 3](#BIO021758F3){ref-type="fig"}I,J,L) appeared in the presence of activin A and FGF2. However, no cells expressing Foxa2 only were observed under this condition. This may be due to the addition of both activin A and FGF2. Fig. 3.**Developmental capacities of single DRG cells.** E12 mouse DRG explants were cultured for 2 days and clonal culture analysis was subsequently performed in the presence of differentiation promoting factors for 5 days. Immunostaining using anti-SMA and anti-NF68, anti-SMA and anti-Foxa2, or anti-SMA and anti-GFAP was carried out on culture day 7. (A) Anti-SMA-positive cells. (B) Anti-NF68-positive cells in the same field as A. (C) DAPI nuclear staining of the same field as A. (D) Merged image of A-C. (E) Anti-SMA-positive cells. (F) Anti-Foxa2-positive cells in the same field as E. (G) DAPI nuclear staining of the same field as E. (H) Merged image of E-G. (I) Anti-GFAP-positive cells. (J) Anti-Foxa2-positive cells in the same field as I. (K) DAPI nuclear staining of the same field as I. (L) Merged image of I-K. B′ shows enlarged images of boxed region in B. Blue arrowheads indicate anti-SMA-positive cells (A,C,D,E,G, and H) or anti-GFAP-positive cells (I,K, and L). Orange arrowheads indicate anti-NF68-positive cells (B-D) or anti-Foxa2-positive cells (F-H). White arrows of I-L indicate cells expressing both GFAP and Foxa2. Scale bars: 50 µm.

In addition, we investigated the *in vivo* developmental capacities of the DRG cells by using a teratoma formation assay. When 4--5-week-old athymic nude mice were injected with dissociated DRG cells, teratomas were formed ([Fig. 4](#BIO021758F4){ref-type="fig"}A). The teratomas contained ectoderm-derived tissues ([Fig. 4](#BIO021758F4){ref-type="fig"}B,C), mesoderm-derived tissues ([Fig. 4](#BIO021758F4){ref-type="fig"}D-I), and endodermal cells expressing Sox17 ([Fig. 4](#BIO021758F4){ref-type="fig"}J-M) or Foxa2 ([Fig. 4](#BIO021758F4){ref-type="fig"}N-Q). Fig. 4.***In vivo* developmental capacities of mouse embryonic DRG cells.** (A) Teratomas were harvested at 2-3 months after injection of dissociated cells derived from E12 mouse DRGs. (B) Glia (Gl) and neuron (Ne). (C) Nerve fiber. (D) Bone and bone marrow. (E) Bone matrix (Bm) and osteocytes (Ocy) in enlarged images of one of the boxed regions in D. (F) Megakaryocyte (Meg), hematopoietic cells (Hec), and red blood cells (Rbc) in enlarged images of the boxed regions in D. (G) Chondrocytes (Ccy). (H) Adipocytes. (I) Smooth muscle (Sm). (J) Bright-field image. (K) Anti-Sox17-positive cells in the same field as J. (L) DAPI nuclear staining of the same field as J. (M) Merged image of K and L. White arrowheads in K-M indicate typical cells containing Sox17. (N) Bright-field image. (O) Anti-Foxa2-positive cells in the same field as N. (P) DAPI nuclear staining of the same field as N. (Q) Merged image of O and P. White arrowheads in O-Q indicate typical cells containing Foxa2. Scale bars: 200 µm in A; 50 µm in D; 20 µm in B,C,E-J, and N.

Maintenance of expression of pluripotency-related transcription factors by addition of leukemia inhibitory factor (LIF)/BMP2/FGF2 {#s2c}
---------------------------------------------------------------------------------------------------------------------------------

Mouse embryonic and adult DRGs contain multipotent NCSCs ([@BIO021758C66]; [@BIO021758C28]; [@BIO021758C54]). It has been reported that Wnt/β-catenin activity plays important roles in NCSC formation in DRGs ([@BIO021758C37]; [@BIO021758C21]). However, there is a loss of this activity in mouse DRGs around E12 ([@BIO021758C37]). Thus, little is known about the mechanisms of the maintenance of multipotency of NCSCs in DRGs after mouse E12. To unravel these mechanisms, we explored signaling molecules that promote the maintenance of multipotency of NCSCs in E12 mouse DRGs. Based on the findings of previous studies using mouse neural crest cells ([@BIO021758C53]; [@BIO021758C21]), mouse ES cells ([@BIO021758C91]; [@BIO021758C26]; [@BIO021758C62]), and adult mouse brain neural stem progenitor cells ([@BIO021758C40]), we focused on LIF, Wnt3a, BMP2, FGF2, and epidermal growth factor (EGF). The number of cells expressing both chromodomain helicase DNA-binding protein 7 (CHD7) and Sox10, markers of multipotent NCSCs in mice ([@BIO021758C21]), was counted on explant culture day 6. The percentage of these cells in a DRG cell colony (each colony was derived from a DRG explant) was highest in colonies cultured with the combination of LIF, BMP2, and FGF2 ([Fig. 5](#BIO021758F5){ref-type="fig"}). This result suggests that LIF/BMP2/FGF2 is the most effective in the maintenance of multipotency of NCSCs in mouse DRGs after E12. Fig. 5.**Signaling molecules that promote maintenance of NCSCs in mouse embryonic DRGs.** E12 mouse DRG explants were exposed to signaling molecules for 6 days. Immunostaining was performed using anti-CHD7 or anti-Sox10 on culture day 6. (A) Bright-field image of a culture treated with LIF/BMP2/FGF2. (B) Anti-CHD7-positive cells in the same field as A. (C) Anti-Sox10-positive cells in the same field as A. (D) DAPI nuclear staining of the same field as A. (E) Merged image of B-D. (F) Percentage of cells expressing both CHD7 and Sox10 per DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to untreated cultures. Data are expressed as mean±s.e.m. of separate counts of 5-16 colonies (the number in parentheses above each bar). Scale bar: 50 µm.

Moreover, we examined the effects of LIF/BMP2/FGF2 on the expression of Oct4 in DRG cells in explant cultures. LIF/BMP2/FGF2 treatment promoted the expression of Oct4 ([Fig. 6](#BIO021758F6){ref-type="fig"}). The expression of Oct4 did not decrease over time in LIF/BMP2/FGF2-treated cultures ([Fig. 6](#BIO021758F6){ref-type="fig"}E). In addition, we investigated the effects of the combination of these signaling molecules on the expression of Sox2 and Nanog. When the number of cells expressing both Sox2 and Oct4 or both Nanog and Oct4 was counted on explant culture day 6, the treatment with LIF/BMP2/FGF2 significantly promoted the expression of Sox2 and Nanog ([Fig. 7](#BIO021758F7){ref-type="fig"}A-L). The number of anti-Sox2- or anti-Nanog-positive cells expressing Oct4 was also increased by LIF/BMP2/FGF2 treatment ([Fig. 7](#BIO021758F7){ref-type="fig"}M,N). Fig. 6.**Effects of LIF/BMP2/FGF2 on expression of Oct4.** E12 mouse DRG explants were exposed to signaling molecules for 2, 4, 6, or 9 days. Immunostaining was performed using anti-Oct4 on culture day 2, 4, 6, or 9. (A) Bright-field image of a culture treated with LIF/BMP2/FGF2 for 6 days. (B) Anti-Oct4-positive cells in the same field as A. (C) DAPI nuclear staining of the same field as A. (D) Merged image of B and C. (E) Percentage of cells expressing Oct4 per DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to the cultures at 2 days under the respective conditions. Data are expressed as mean±s.e.m. of separate counts of 5-12 colonies (the number in parentheses above each bar). Scale bar: 50 µm. Fig. 7.**Effects of LIF/BMP2/FGF2 on expression of Sox2 and Nanog.** E12 mouse DRG explants were cultured in medium containing LIF/BMP2/FGF2 for 6 days. Immunostaining was performed using anti-Oct4, anti-Sox2, or anti-Nanog on culture day 6. (A) Bright-field image of a culture treated with LIF/BMP2/FGF2. (B) Anti-Sox2-positive cells in the same field as A. (C) Anti-Oct4-positive cells in the same field as A. (D) DAPI nuclear staining of the same field as A. (E) Merged image of B-D. (F) Bright-field image of LIF/BMP2/FGF2-treated culture. (G) Anti-Nanog-positive cells in the same field as F. (H) Anti-Oct4-positive cells in the same field as F. (I) DAPI nuclear staining of the same field as F. (J) Merged image of G-I. (K) Percentage of cells expressing Sox2 per DRG cell colony. (L) Percentage of cells expressing Nanog per DRG cell colony. (M) Percentage of cells expressing both Oct4 and Sox2 per total cells expressing Sox2 in a DRG cell colony. (N) Percentage of cells coexpressing Oct4 and Nanog per total cells expressing Nanog in a DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to untreated cultures. Data are expressed as mean±s.e.m. of separate counts of 6-10 colonies (the number above the parentheses on each bar). Scale bars: 50 µm.

Developmental capacities of mouse embryonic DRG cells treated with LIF/BMP2/FGF2 {#s2d}
--------------------------------------------------------------------------------

LIF/BMP2/FGF2 treatment thus promoted the expression of pluripotency-related transcription factors in mouse embryonic DRG cells. Therefore, we examined the developmental potentials of DRG cells treated with LIF/BMP2/FGF2. DRG explants were cultured in medium containing LIF/BMP2/FGF2 during the first 6 days and subsequently exposed to various differentiation-promoting factors ([Fig. 8](#BIO021758F8){ref-type="fig"}A). These cells differentiated into neurons in BMP4-treated cultures ([Fig. 8](#BIO021758F8){ref-type="fig"}B-E), into glia in FGF2-treated cultures ([Fig. 8](#BIO021758F8){ref-type="fig"}F-I), into smooth muscle cells in TGFβ-treated cultures ([Fig. 8](#BIO021758F8){ref-type="fig"}J-M), into chondrocytes in FGF2-treated cultures ([Fig. 8](#BIO021758F8){ref-type="fig"}N-Q), into anti-Sox17-positive endodermal cells in activin A-treated cultures ([Fig. 8](#BIO021758F8){ref-type="fig"}R-U), and into anti-Foxa2-positive endodermal cells in activin A-treated cultures ([Fig. 8](#BIO021758F8){ref-type="fig"}V-Y). On the other hand, when DRG explants were cultured for 6 days under the control condition that did not contain LIF/BMP2/FGF2, the differentiation into neurons, glia, and chondrocytes was dramatically suppressed ([Fig. S1](Fig. S1)). Fig. 8.**Developmental capacities of mouse embryonic DRG cells in explant cultures containing LIF/BMP2/FGF2.** (A) E12 mouse DRG explants were cultured in medium containing LIF/BMP2/FGF2 during the first 6 days and subsequently exposed to differentiation-promoting factors for 4 or 6 days. Immunostaining was performed using anti-NF68, anti-GFAP, anti-SMA, anti-Collagen type II, anti-Sox17, or anti-Foxa2 on culture day 10 or 12. (B) Bright-field image. (C) Anti-NF68-positive cells in the same field as B. (D) DAPI nuclear staining of the same field as B. (E) Merged image of C and D. (F) Bright-field image. (G) Anti-GFAP-positive cells in the same field as F. (H) DAPI nuclear staining of the same field as F. (I) Merged image of G and H. (J) Bright-field image. (K) Anti-SMA-positive cells in the same field as J. (L) DAPI nuclear staining of the same field as J. (M) Merged image of K and L. (N) Bright-field image. (O) Anti-Collagen type II-positive cells in the same field as N. (P) DAPI nuclear staining of the same field as N. (Q) Merged image of O and P. (R) Bright-field image. (S) Anti-Sox17-positive cells in the same field as R. (T) DAPI nuclear staining of the same field as R. (U) Merged image of S and T. (V) Bright-field image. (W) Anti-Foxa2-positive cells in the same field as V. (X) DAPI nuclear staining of the same field as V. (Y) Merged image of W and X. Scale bars: 50 µm.

Moreover, we carried out clonal culture analysis to examine the developmental capacities of single cells derived from the DRG explants treated with LIF/BMP2/FGF2. We found clones containing both smooth muscle cells ([Fig. 9](#BIO021758F9){ref-type="fig"}A,D) and neurons ([Fig. 9](#BIO021758F9){ref-type="fig"}B,D) in BMP4-treated cultures. We also observed clones containing both smooth muscle cells ([Fig. 9](#BIO021758F9){ref-type="fig"}E,H) and endodermal cells expressing Foxa2 ([Fig. 9](#BIO021758F9){ref-type="fig"}F,H) in activin A-treated cultures. Clones containing cells which express both GFAP and Foxa2 ([Fig. 9](#BIO021758F9){ref-type="fig"}I,J,L) appeared in the presence of activin A and FGF2. However, no cells expressing Foxa2 only were observed under this condition. Fig. 9.**Developmental capacities of single cells derived from E12 mouse DRG explants treated with LIF/BMP2/FGF2.** The DRG explants were cultured in the medium containing LIF/BMP2/FGF2 for 2 days and clonal culture analysis was subsequently performed in the presence of differentiation promoting factors for 5 days. Immunostaining using anti-SMA and anti-NF68, anti-SMA and anti-Foxa2, or anti-SMA and anti-GFAP was carried out on culture day 7. (A) Anti-SMA-positive cells. (B) Anti-NF68-positive cells in the same field as A. B′ shows enlarged images of boxed region in B. (C) DAPI nuclear staining of the same field as A. (D) Merged image of A-C. (E) Anti-SMA-positive cells. (F) Anti-Foxa2-positive cells in the same field as E. (G) DAPI nuclear staining of the same field as E. (H) Merged image of E-G. (I) Anti-GFAP-positive cells. (J) Anti-Foxa2-positive cells in the same field as I. (K) DAPI nuclear staining of the same field as I. (L) Merged image of I-K. Blue arrowheads indicate anti-SMA-positive cells (A,C,D,E,G, and H) or anti-GFAP-positive cells (I,K, and L). Orange arrowheads indicate anti-NF68-positive cells (B-D) or anti-Foxa2-positive cells (F-H). White arrows of I-L indicate cells expressing both GFAP and Foxa2. Scale bars: 50 µm.

Additionally, we performed the teratoma formation assay using cells dissociated from the DRG explants cultured for 6 days in the presence of LIF/BMP2/FGF2, and found that teratomas were formed by injecting dissociated DRG cells treated with LIF/BMP2/FGF2 ([Fig. 10](#BIO021758F10){ref-type="fig"}A). The teratomas contained ectoderm-derived tissues ([Fig. 10](#BIO021758F10){ref-type="fig"}B,C), mesoderm-derived tissues ([Fig. 10](#BIO021758F10){ref-type="fig"}D-F), and endoderm-derived tissue ([Fig. 10](#BIO021758F10){ref-type="fig"}G). Endodermal cells expressing Sox17 ([Fig. 10](#BIO021758F10){ref-type="fig"}H-K) or Foxa2 ([Fig. 10](#BIO021758F10){ref-type="fig"}L-O) were observed. By contrast, no teratomas were formed by injecting cells dissociated from the DRG explants cultured for 6 days under the control condition. Fig. 10.***In vivo* developmental capacities of mouse embryonic DRG cells treated with LIF/BMP2/FGF2.** (A) Teratomas were harvested at 2-3 months after injection of dissociated cells that had been derived from E12 mouse DRG explants cultured for 6 days in medium containing LIF/BMP2/FGF2. (B) Glia (Gl) and neuron (Ne). (C) Hair (Hr). (D) Cartilage. (E) Adipocytes. (F) Connective tissue. (G) Alveolar epithelium-like structure. (H) Bright-field image. (I) Anti-Sox17-positive cells in the same field as H. (J) DAPI nuclear staining of the same field as H. (K) Merged image of I and J. White arrowheads in I-K indicate typical cells containing Sox17. (L) Bright-field image. (M) Anti-Foxa2-positive cells in the same field as L. (N) DAPI nuclear staining of the same field as L. (O) Merged image of M and N. White arrowheads in M-O indicate typical cells containing Foxa2. Scale bars: 200 µm in A; 20 µm in B-H and L.

Proliferation of Oct4-expressing DRG cells {#s2e}
------------------------------------------

We then examined the proliferation of anti-Oct4-positive DRG cells in LIF/BMP2/FGF2-treated cultures. The number of cells expressing proliferating cell nuclear antigen (PCNA) was counted on explant culture day 6. The percentage of anti-PCNA-positive proliferating cells per DRG cell colony was increased by treatment with LIF/BMP2/FGF2 ([Fig. 11](#BIO021758F11){ref-type="fig"}K). The proportion of anti-PCNA-positive cells per total Oct4-expressing cells was also increased by this treatment ([Fig. 11](#BIO021758F11){ref-type="fig"}A-E,L). 4′,6-Diamidino-2-phenylindole (DAPI) nuclear staining showed that almost no cell death occurred in cultures treated with LIF/BMP2/FGF2. Therefore, we assessed apoptosis under the control and LIF/BMP2/FGF2-treated conditions. No significant difference of the proportion of apoptotic cell death was found between these conditions ([Fig. 11](#BIO021758F11){ref-type="fig"}M). Moreover, no cells expressing both caspase-3 and Oct4 ([Fig. 11](#BIO021758F11){ref-type="fig"}F-J) were observed. Fig. 11.**Effects of LIF/BMP2/FGF2 on proliferation of mouse embryonic DRG cells.** E12 mouse DRG explants were cultured in medium containing LIF/BMP2/FGF2 for 6 days. Immunostaining was performed using anti-PCNA, anti-Oct4, and anti-Caspase-3 on culture day 6. (A) Bright-field image of a culture treated with LIF/BMP2/FGF2. (B) Anti-PCNA-positive cells in the same field as A. (C) Anti-Oct4-positive cells in the same field as A. (D) DAPI nuclear staining of the same field as A. (E) Merged image of B-D. (F) Bright-field image of the untreated culture. (G) Anti-Cacpase-3-positive cells in the same field as F. (H) Anti-Oct4-positive cells in the same field as F. (I) DAPI nuclear staining of the same field as F. (J) Merged image of G-I. (K) Percentage of cells expressing PCNA per DRG cell colony. (L) Percentage of cells coexpressing PCNA and Oct4 per total cells expressing PCNA in a DRG cell colony. (M) Percentage of cells expressing Caspase-3 per DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to untreated cultures. Data are expressed as mean±s.e.m. of separate counts of 6-10 colonies (the number in parentheses above each bar). (N) Time course of average diameter of spheres in suspension cultures of dissociated cells derived from E12 mouse DRGs. Data are expressed as mean±s.e.m. of separate measurements of four spheres. †*P*\<0.05 (Student\'s *t*-test) compared to untreated suspension cultures. (O) Bright-field image of a sphere cultured in the medium containing LIF/BMP2/FGF2 for 6 days. (P) Bright-field image of a sphere in the untreated culture at 6 days. Scale bars: 50 µm.

ES cells generate embryoid body (EB)-like spheres in suspension cultures ([@BIO021758C38]; [@BIO021758C42]). Therefore, we examined whether or not DRG cells form spheres in suspension culture. The DRG cells formed spheres both with and without LIF/BMP2/FGF2 treatment ([Fig. 11](#BIO021758F11){ref-type="fig"}O,P). However, the size of the spheres was significantly increased by the addition of LIF/BMP2/FGF2 ([Fig. 11](#BIO021758F11){ref-type="fig"}N).

Formation of primordial germ cell-like cells (PGCLCs) from mouse embryonic DRG cells {#s2f}
------------------------------------------------------------------------------------

Mouse ES cells have been known to form PGCLCs expressing B lymphocyte-induced maturation protein 1 (Blimp1) and Oct4 in LIF/BMP4-treated cultures ([@BIO021758C41]). Therefore, we investigated whether or not mouse embryonic DRG cells form PGCLCs. DRG explants were cultured on the time schedules shown in [Fig. 12](#BIO021758F12){ref-type="fig"}F. Since high concentrations of fetal bovine serum (FBS) block the formation of PGCLCs ([@BIO021758C63]), we used Nu-serum instead of FBS and chick embryo extract (CEE). The culture condition containing 10% Nu-serum was the most effective in the formation of PGCLCs expressing both Blimp1 and Oct4 ([Fig. 12](#BIO021758F12){ref-type="fig"}A-E,G). There were no significant differences of PGCLC formation between the DRG explants treated with LIF/BMP4 only and those treated with LIF/BMP2/FGF2 and then LIF/BMP4 ([Fig. 12](#BIO021758F12){ref-type="fig"}G). Fig. 12.**PGCLC formation by mouse embryonic DRG cells.** E12 mouse DRG explants were cultured for 2 or 8 days. Immunostaining was performed using anti-Blimp1 and anti-Oct4 on culture day 2 or 8. (A) Bright-field image of a culture treated with LIF/BMP2/FGF2 during the first 6 days and subsequently exposed to 10% Nu-serum and LIF/BMP4 for 2 days. (B) Anti-Blimp1-positive cells in the same field as A. (C) Anti-Oct4-positive cells in the same field as A. (D) DAPI nuclear staining of the same field as A. (E) Merged image of B-D. White arrowheads in B-E indicate cells expressing both Blimp1 and Oct4. Scale bar: 50 µm. (F) Culture schedules of E12 mouse DRG explants for inducing the formation of PGCLCs. (G) Percentage of cells expressing both Blimp1 and Oct4 per DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to the cultures treated with LIF/ BMP4 for 2 days. Data are expressed as mean±s.e.m. of separate counts of 6-11 colonies (the number in parentheses above each bar).

Oct4, Sox2, and Nanog have been shown to interact with each other in mouse ES cells ([@BIO021758C65]; [@BIO021758C10]). Therefore, we examined the interactions among Oct4, Sox2, and Nanog in cells dissociated from E12 mouse DRGs ([Fig. S2A](Fig. S2A),[B](B)), in cells dissociated from the DRG explants cultured for 6 days under the control condition ([Fig. S2C](Fig. S2C),[D](D)), and in cells dissociated from the DRG explants cultured for 6 days in the presence of LIF/BMP2/FGF2 ([Fig. S2E](Fig. S2E),[F](F)) by micro chromatin immunoprecipitation (µChIP)-quantitative real-time polymerase chain reaction (qPCR) analysis. The interactions among these transcription factors in DRG cells dissociated from E12 mouse DRGs and in DRG cells treated with LIF/BMP2/FGF2 were similar to those in mouse ES cells ([Fig. S2B](Fig. S2B),[F](F)).

Relationship between NCSCs and PSCs {#s2g}
-----------------------------------

Our data presented above suggest that mouse embryonic DRGs contain PSCs with characteristics similar to those of ES cells. Therefore, we examined the correlation between PSCs and NCSCs. In mouse embryonic DRGs at E12, there were DRG cells that expressed Oct4 ([Fig. 13](#BIO021758F13){ref-type="fig"}B,E) and CHD7, a marker of NCSCs ([Fig. 13](#BIO021758F13){ref-type="fig"}C,E). Furthermore, cells expressing both Oct4 and CHD7 were observed in the DRGs (white arrowheads in [Fig. 13](#BIO021758F13){ref-type="fig"}B′-E′). Fig. 13.**Coexpression of Oct4 and CHD7 in mouse embryonic DRGs.** (A-E) Transverse sections of E12 mouse DRGs. The top, bottom, left, and right of each photograph correspond to the dorsal, ventral, proximal, and distal side of embryo, respectively. (A) Bright-field image. (B) Expression pattern of Oct4 in the same field as A. (C) Expression pattern of CHD7 in the same field as A. (D) DAPI nuclear staining of the same field as A. (E) Merged image of B-D. A′-E′ show enlarged images of boxed regions in A-E. White arrowheads in B′-E′ indicate cells expressing both Oct4 and CHD7. (F-L) *In vitro* coexpression of Oct4 and CHD7 in E12 mouse DRG explants on culture day 2, 4, 6, and 9. (F) Bright-field image of a culture treated with LIF/BMP2/FGF2 for 6 days. (G) Anti-Oct4-positive cells in the same field as F. (H) Anti-CHD7-positive cells in the same field as F. (I) DAPI nuclear staining of the same field as F. (J) Merged image of G-I. (K) Percentage of cells expressing both Oct4 and CHD7 per DRG cell colony. (L) Percentage of cells coexpressing Oct4 and CHD7 per total cells expressing CHD7 in a DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to the cultures at 2 days under the respective conditions. Data are expressed as mean±s.e.m. of separate counts of 5-12 colonies (the number in parentheses above each bar). Scale bars: 20 µm in A and A′; 50 µm in F.

We then explored whether the expression of Oct4 in mouse NCSCs is promoted by the addition of LIF/BMP2/FGF2. The percentage of cells expressing both Oct4 and CHD7 per DRG cell colony was drastically increased, and then never decreased over the culture period, by LIF/BMP2/FGF2 treatment ([Fig. 13](#BIO021758F13){ref-type="fig"}F-K). The proportion of cells expressing both Oct4 and CHD7 per total anti-CHD7-positive cells was also maintained over the culture period by the addition of LIF/BMP2/FGF2 ([Fig. 13](#BIO021758F13){ref-type="fig"}L).

In addition, we analyzed the regulatory interactions between pluripotency-related transcription factors, Oct4, Sox2, and Nanog, and the factors that characterize mouse NCSCs, CHD7 and Sox10. Mouse embryonic DRG cells in explant cultures were treated with expression vectors and small interfering (si) RNAs, as shown in [Fig. 14](#BIO021758F14){ref-type="fig"}A. Whereas the expression of Sox10 and Oct4 was promoted by treatment with the wild-type (WT) CHD7 expression vector ([Fig. 14](#BIO021758F14){ref-type="fig"}C,F), their expression was significantly suppressed by the dominant-negative (DN) CHD7 expression vector or *CHD7* siRNA in the presence of LIF/BMP2/FGF2 ([Fig. 14](#BIO021758F14){ref-type="fig"}C,F). Furthermore, the expression of CHD7 and Sox10 was suppressed by *Oct4*, *Sox2*, and *Nanog* siRNA in the presence of LIF/BMP2/FGF2 ([Fig. 14](#BIO021758F14){ref-type="fig"}B,C,E). Coexpression of CHD7 and Sox10 or of CHD7 and Oct4 was affected by these expression vectors and siRNAs ([Fig. 14](#BIO021758F14){ref-type="fig"}D,G). Thus, pluripotency-related transcription factors have regulatory interactions with the factors that characterize mouse NCSCs. When the DN CHD7 expression vectors were added, the number of anti-CHD7-positive cells increased ([Fig. 14](#BIO021758F14){ref-type="fig"}B,E), indicating that the anti-CHD7 antibody used in this study recognized the mutant CHD7, probably due to the fact that the mutation in this protein changed only lysine 998 in the ATPase domain of CHD7 to arginine. Fig. 14.**Effects of WT CHD7 or DN CHD7 expression vectors and of *CHD7*, *Oct4*, *Sox2*, or *Nanog*** **siRNAs on CHD7, Sox10, or Oct4 expression.** (A) E12 mouse DRG explants were exposed to LIF/BMP2/FGF2 for 6 days. Each expression vector or siRNA was applied from day 0 to day 2 in culture. (B) Percentage of cells expressing CHD7 per DRG cell colony. (C) Percentage of cells expressing Sox10 per DRG cell colony. (D) Percentage of cells expressing both CHD7 and Sox10 per DRG cell colony. (E) Percentage of cells expressing CHD7 per DRG cell colony. (F) Percentage of cells expressing Oct4 per DRG cell colony. (G) Percentage of cells expressing both CHD7 and Oct4 per DRG cell colony. \**P*\<0.05 (Student\'s *t*-test) compared to untreated cultures. †*P*\<0.05 (Student\'s *t*-test) compared to LIF/BMP2/FGF2-treated cultures. Data are expressed as mean±s.e.m. of separate counts of 5-15 colonies (the number in parentheses above each bar).

DISCUSSION {#s3}
==========

In the present study, we showed that mouse embryonic DRGs contain cells that express pluripotency-related transcription factors Oct4, Sox2, and Nanog. It has been reported that Oct4 ([@BIO021758C55]; [@BIO021758C57]), Sox2 ([@BIO021758C3]; [@BIO021758C47]), and Nanog ([@BIO021758C9]; [@BIO021758C48]) function in the maintenance of pluripotency in both early mouse embryos and ES cells. Furthermore, the DRGs expressed SSEA1 and showed alkaline phosphatase activity, which have been known to be pluripotency markers in mouse ES and induced pluripotent stem (iPS) cells ([@BIO021758C88]; [@BIO021758C14]; [@BIO021758C75]). In addition, we showed here that DRG cells differentiated into ectoderm-, mesoderm-, and endoderm-derived cells in explant cultures. In clonal cultures, we also found clones containing both ectoderm (neurons)- and mesoderm (smooth muscle cells)-derived cells, both endodermal cells (Foxa2-expressing cells) and mesoderm-derived cells, or cells expressing both ectoderm-derived phenotype (GFAP) and endodermal phenotype (Foxa2). These data suggest that some of the single DRG cells may have ability to differentiate into cells which originate from three germ layers.

Moreover, the DRG cells formed teratomas that contained ectoderm-, mesoderm-, and endoderm-derived cells, like the teratomas formed by ES cells ([@BIO021758C81]) and by iPS cells ([@BIO021758C75]). The DRG cells also had sphere-forming capacity, as do ES cells ([@BIO021758C17]; [@BIO021758C33]) and iPS cells ([@BIO021758C75]). Furthermore, the DRG cells formed PGCLCs. This feature is also similar to that of ES cells ([@BIO021758C30]; [@BIO021758C84]; [@BIO021758C27]) and iPS cells ([@BIO021758C27]). These data suggest that mouse embryonic DRGs contain PSCs with characteristics like those of ES cells and iPS cells.

Mouse embryonic DRGs cells formed teratomas containing bone marrow, in which megakaryocytes, hematopoietic cells, and red blood cells were observed. It has been reported that iPS cells form hematopoietic stem cells through teratoma formation ([@BIO021758C74]). DRG cells may also have the capacity to form hematopoietic stem cells.

It has been shown that mouse embryonic and adult DRGs contain multipotent NCSCs ([@BIO021758C66]; [@BIO021758C28]; [@BIO021758C54]), and that Wnt/BMP signaling plays important roles in the formation of NCSCs ([@BIO021758C37]; [@BIO021758C21]). Moreover, we demonstrated that the Wnt/β-catenin pathway is essential in this process ([@BIO021758C21]). However, Wnt/β-catenin activity disappears in mouse DRGs around E12 ([@BIO021758C37]). Thus, different signaling molecules may participate in the maintenance of multipotency of NCSCs in mouse DRGs. The present study showed that LIF/BMP2/FGF2 was the most effective tested combination of factors for the maintenance of multipotency of NCSCs in mouse DRGs at E12. These data suggest that Wnt/BMP signaling works for the formation of NCSCs and LIF/BMP2/FGF2 signaling is involved in the maintenance of multipotency of NCSCs during mouse DRG development. While LIF maintains the pluripotency of mouse ES cells, BMP2/4 and FGF play supportive roles in the maintenance of their pluripotency ([@BIO021758C91]; [@BIO021758C58]; [@BIO021758C76]). Furthermore, FGF2 has been implicated in the maintenance of pluripotency of human ES cells ([@BIO021758C85]; [@BIO021758C44]). Therefore, we analyzed the effects of LIF/BMP2/FGF2 on the maintenance of pluripotency of PSCs in mouse embryonic DRGs. The addition of LIF/BMP2/FGF2 maintained the expression of Oct4, Sox2, and Nanog. The DRG cells sustained the capacities to differentiate into ectoderm-, mesoderm-, and endoderm-derived cells *in vitro* and *in vivo*, even after the cells were treated with LIF/BMP2/FGF2. In addition, the DRG cells treated with LIF/BMP2/FGF2 formed spheres and PGCLCs. These findings indicate that LIF/BMP2/FGF2 participates not only in the maintenance of multipotency of NCSCs, but also in the maintenance of pluripotency of PSCs in mouse embryonic DRGs.

LIF/BMP2/FGF2 promoted cell proliferation of the DRG cells in both explant and suspension cultures. Moreover, LIF/BMP2/FGF2 treatment stimulated the proliferation of the DRG cells expressing Oct4. Thus, the combination of these signaling molecules may promote the proliferation of PSCs as well as the maintenance of pluripotency of PSCs in mouse embryonic DRGs.

Mouse and rat DRG cells have been shown to express LIF, BMP2, and FGF2 ([@BIO021758C52], [@BIO021758C53]; [@BIO021758C20]). The expression of receptors for these signaling molecules in DRGs has also been reported ([@BIO021758C5]; [@BIO021758C87]; [@BIO021758C93]). Thus, LIF/BMP2/FGF2 signaling may play important roles in the maintenance of pluripotency of PSCs in mouse embryonic DRGs *in vivo*.

Since LIF/BMP2/FGF2 was involved both in the maintenance of the expression of pluripotency-related transcription factors (Oct4, Sox2, and Nanog) and in the maintenance of the expression of factors that characterize mouse NCSCs (CHD7 and Sox10), we analyzed the relationship between pluripotency-related transcription factors and the factors that characterize mouse NCSCs in mouse embryonic DRGs. DRG cells expressing both Oct4 and CHD7 were observed *in vivo* and *in vitro*. The number of these cells *in vitro* was dramatically increased by LIF/BMP2/FGF2 treatment. Furthermore, the expression of Oct4 was suppressed by inhibiting the expression of CHD7 and the expression of CHD7 and Sox10 was repressed by *Oct4*, *Sox2*, and *Nanog* siRNA in the presence of LIF/BMP2/FGF2. These findings reveal that pluripotency-related transcription factors and factors that characterize mouse NCSCs were mutually regulated by each other in mouse embryonic DRGs. Thus, PSCs in mouse embryonic DRGs may be NCSCs in the DRGs. It has been shown that CHD7 binds to enhancer elements of Oct4, Sox2, and Nanog in mouse ES cells ([@BIO021758C68]) and these cells express Sox10, although at a low level compared with that in neural crest cells ([@BIO021758C23]). Taken together, all these findings support the notion that NCSCs in mouse embryonic DRGs may have equivalent developmental potential to PSCs such as ES cells and iPS cells.

MATERIALS AND METHODS {#s4}
=====================

Animals {#s4a}
-------

We used pregnant ddY mice and 4--5-week-old KSN/Slc athymic nude mice (male) in the present study. ddY and nude mice were purchased from Japan SLC, Inc (Shizuoka, Japan). The mouse experiments were approved by the Animal Experimentation Committee of Osaka University. Mice were treated humanely, and all mouse experiments were made under conditions designed to minimize suffering.

Explant cultures {#s4b}
----------------

Explant cultures of mouse embryonic DRGs were prepared from ddY mouse embryos at E12 ([@BIO021758C21]). DRGs were isolated from the trunk regions between forelimbs and hindlimbs by the methods described previously ([@BIO021758C25]; [@BIO021758C73]). The isolated DRGs were explanted into 35-mm culture dishes coated with collagen gel (Cellmatrix, Nitta Gelatin, Osaka, Japan). The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO~2~, and the culture medium (see the 'Culture medium and signaling molecules' section) was changed every other day.

Suspension cultures {#s4c}
-------------------

DRGs were dissociated according to a modification of methods described previously ([@BIO021758C51]; [@BIO021758C29]). The isolated DRGs were minced and then incubated in 0.025% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) for 12 min at 37°C. For suspension cultures, the dissociated DRG cells were triturated using fire-polished Pasteur pipettes until they formed a single-cell suspension (\>95% single cells). The cell suspension was seeded at 2000 cells/well onto a wall of a low-adhesion surface U-bottom 96-well plate (IWAKI, Tokyo, Japan) to examine the formation of EB-likes spheres. The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO~2~, and the culture medium (see the 'Culture medium and signaling molecules' section) was added 75 µl per 2 days.

Clonal cultures {#s4d}
---------------

Clonal cultures of mouse embryonic DRG cells were performed by a modification of methods described previously ([@BIO021758C32]). DRGs were dissected and cut into small fragments. These fragments were explanted into 35-mm culture dishes coated with collagen gel (Cellmatrix, Nitta Gelatin). Two days later, DRG cells derived from these fragments were resuspended by trypsinization. This essentially single cell suspension (\>95% single cells) was diluted to 100 cells/ml. One milliliter aliquots of this diluted cell suspension were plated to 35-mm culture dishes that were coated with a collagen gel (PureCol, Advanced BioMatrix, San Diego, CA, USA) and conditioned with culture medium (see the 'Culture medium and signaling molecules' section) containing 10 µg/ml plasma fibronectin (Sigma, St. Louis, MO, USA). The clone founder cells were identified at 8 h after seeding cells. The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO~2~, and the culture medium was changed every day for the first 2 days and then every other day.

Culture medium and signaling molecules {#s4e}
--------------------------------------

The culture medium consisted of 85% α-modified minimum essential medium (α-MEM, Sigma), 10% FBS (GE Healthcare Life Sciences, Pittsburgh, PA, USA), 5% CEE, and 50 µg/ml gentamicin (Sigma). We used 1% or 10% Nu-serum (Becton Dickinson, Lincoln Park, IL, USA) instead of FBS and CEE in the formation of PGCLCs.

LIF (Wako, Osaka, Japan) was added to the medium at 1000 units/ml. Wnt3a (PeproTech, Rocky Hill, CT, USA), BMP2 (R&D Systems, Minneapolis, MN, USA), BMP4 (a gift from the Genetic Institute, Andover, MA, USA), FGF2 (R&D Systems, PeproTech), EGF (PeproTech), TGFβ (PeproTech), and activin A (PeproTech) were used at 10 ng/ml, 10 ng/ml, 10 ng/ml, 10 ng/ml, 2-10 ng/ml, 0.1 ng/ml, and 100 ng/ml, respectively.

Transfection of expression vectors and siRNAs {#s4f}
---------------------------------------------

Mouse embryonic DRG cells in explant cultures were transfected with 1 µg of the following expression vectors: (1) pcDNA3.1 encoding human WT CHD7 and a Flag-6×His tag (a gift from Dr J. Wysocka, Stanford University, Stanford, USA; [@BIO021758C4]), (2) pcDNA3.1 encoding human DN CHD7 and a Flag-6×His tag (a gift from Dr J. Wysocka; [@BIO021758C4]). Transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for the first 48 h in culture.

The siRNA duplexes for *CHD7*, *Oct4*, *Sox2*, and *Nanog* were designed based on their sequences published online (GenBank Accession Nos. NM_001081417, NM_013633, NM_011443, NM_028016). All siRNA sequences are listed in [Table S1](Table S1). Stealth™ RNAi Negative Control Medium GC Duplex \#2 (Invitrogen) was used as the control for *CHD7*, *Oct4*, *Sox2*, or *Nanog* siRNA. Using Lipofectamine 2000, mouse embryonic DRG cells were transfected with 40 nM *CHD7* siRNA, *Oct4* siRNA, *Sox2* siRNA, *Nanog* siRNA, or the RNAi Negative Control for the first 48 h in culture.

Immunostaining {#s4g}
--------------

Explant and clonal cultures were fixed with 4% paraformaldehyde (PFA) for 1 h on ice. The cultures were immunostained with the primary antibodies for 16 h at 4°C, except in the case of immunostaining with anti-Nanog (Santa Cruz, Dallas, TX, USA, sc-30328), which was performed for 1 h at 37°C. The cultures were treated with secondary antibodies for 1 h at room temperature.

Neural tubes with attached DRG were dissected from E12 mouse embryos by the method described previously ([@BIO021758C25]). The neural tubes with attached DRG were fixed with 4% PFA for 1 h on ice. The fixed tissues were immersed in gradually increasing concentrations of sucrose solution and embedded in OCT compound (Miles, Elkhart, IN, USA). Cryostat sections were cut at 10 µm and mounted on albumin-coated glass slides. The sections were immunostained with primary antibodies for 16 h at 4°C and then treated with secondary antibodies for 1 h at room temperature. Finally, the nuclei in cultures and sections were stained with 0.1 µg/ml DAPI (Dojindo, Kumamoto, Japan). DAPI nuclear staining was important for counting the exact number of immunoreactive cells in the DRG cell cultures and for judging cell death. Details of all antibodies used are listed in [Table S2](Table S2).

Alkaline phosphatase staining {#s4h}
-----------------------------

Neural tubes with attached DRG were fixed with 4% PFA for 1 h on ice, and then were cut at 10 µm as cryostat sections. These sections were stained by using alkaline phosphatase staining kit (Wako, 294-67001).

Teratoma formation assay {#s4i}
------------------------

Approximately 5×10^5^ or 10×10^5^ dissociated DRG cells in 50% Cultex BME (Trevigen, Gaithersburg, MD, USA, 3432-001-01) were injected subcutaneously into the dorsal flank of athymic nude mice. The dissociated DRG cells were prepared under the following three different conditions: (1) cells dissociated from mouse E12 DRGs, (2) cells dissociated from the DRG explants cultured for 6 days under the control condition that did not contain any signaling molecules, or (3) cells dissociated from the DRG explants cultured for 6 days under conditions containing LIF/BMP2/FGF2. The animals were sacrificed 2 or 3 months after the injection and tumors were dissected.

Histology {#s4j}
---------

Teratomas were fixed with Bouin\'s fixative and embedded in paraffin. The paraffin sections were cut at 7 µm and mounted on albumin-coated glass slides. After deparaffinization, the sections were stained with Ehrlich\'s hematoxylin and counterstained with eosin and Alcian Blue (pH 2.6). Several teratomas were fixed with 4% PFA for 1 h on ice for immunostaining. These teratomas were treated as described above (see the 'Immunostaining' section) and then immunostained.

µChIP-qPCR analysis {#s4k}
-------------------

μChIP was performed by a modification of methods described previously ([@BIO021758C15]). Mouse embryonic DRGs or DRG cells in explant cultures were dissociated by trypsinization and subsequently triturated using fire-polished Pasteur pipettes until a single-cell suspension (\>95% single cells) was obtained.

The chromatin in these cells was cross-linked by adding formaldehyde at a final concentration of 1% for 8 min at room temperature. The cross-linked cells were washed with phosphate buffered saline containing 20 mM sodium butyrate (NaBu). The pellets of these cells were resuspended and lysed in lysis buffer \[1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, 20 mM NaBu, and protease inhibitor tablet (Complete Protease Inhibitor Mini EDTA-free, Roche, Basel, Switzerland)\] for 5 min on ice. The lysate was diluted fivefold with RIPA buffer \[0.1% SDS, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM ethylene glycol bis (2-aminoethyl ether)-N,N,N\',N\'-tetraacetic acid (EGTA), 0.1% Na-deoxycholate, 1% Triton X-100, and protease inhibitor tablet\] and sonicated using an Advanced Sonifier 250A at output 2, duty cycle 60% for 4×10 s pulses each with a 2-min pause between pulses on ice.

Chromatin fragments were incubated for 2 h at 4°C with 10 μl of Protein G-coated paramagnetic beads that had been preincubated with the appropriate antibodies. The antibodies used for immunoprecipitation are listed in [Table S2](Table S2). The complexes were washed twice with RIPA buffer and once with TE, and were eluted in elution buffer \[1% sodium dodecyl sulfate (SDS), 20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM EDTA, and 20 mM NaBu\] from the beads by heating at 65°C with occasional vortexing. The cross-linking was reversed by incubation at 65°C overnight. DNA was purified by treatment with Proteinase K (0.2 mg/ml; Wako) and phenol/chloroform/isoamyl alcohol.

Real-time PCR reactions were carried out using ABI7300. The PCR reactions were performed in duplicate for each sample. The primer sets were designed using Primer Express 3.0 (Invitrogen) for Oct4 promoter conserved region 4 (CR4; [@BIO021758C59]), Sox2 enhancer Sox regulatory regions 2 (SRR2; [@BIO021758C82]), and Nanog promoter ([@BIO021758C77]). These regions contain Oct-Sox elements and participate in regulating the pluripotency of mouse ES cells ([@BIO021758C11]; [@BIO021758C77]). The primer sequences used for qPCR are shown in [Table S1](Table S1).

Statistical analysis {#s4l}
--------------------

The significance of differences was determined using Student\'s *t*-test. P\<0.05 was considered statistically significant.
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